Products & Tech | Page 44 of 63

EU Finds Novo Nordisk’s Detemir Safe for Children Aged 2-5

The European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the extended use of Novo Nordisk’s basal insulin analogue, insulin detemir, in children with type 1 diabetes, aged two to five years. The CHMP decision was made after the review of data demonstrating that insulin detemir...

Takeda Launches New Type 2 Diabetes Combination Drug

Takeda Pharmaceutical announced the launch of LIOVEL®, a fixed dose combination tablet of NESINA® (alogliptin) and ACTOS® (pioglitazone HCl) for treatment of type 2 diabetes. LIOVEL is a tablet taken orally once daily and has two dosage strengths

First Mobile Diabetes Management System Approved by EU

The UK-based company, Cellnovo, received CE Mark approval for the world’s first mobile diabetes management system, a significant milestone for the company and for people living with diabetes. Cellnovo is a complete diabetes management system built around the principles of mobile, wireless technology. The system includes an insulin patch pump, a wireless, touch screen handset with a built-in blood glucose monitor, and an extendable applications set...

Adding ONGLYZA to Insulin in Adults with Type 2 Diabetes Found Effective

Results of an investigational Phase 3b clinical study, presented by Bristol-Myers Squibb Company and AstraZeneca at the 47th European Association for the Study of Diabetes (EASD), have shown that adding ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes...

Novo Nordisk’s New Ultra-Long-Acting Insulin Proves Effective for Treatment of Type 2 Diabetes

Novo Nordisk's ultra-long-acting insulin degludec, an investigational basal insulin being developed, showed significant blood sugar reductions in patients with type 2 diabetes even when doses were given once-daily up to 40 hours apart, according to data presented today at the European Association for the Study of Diabetes (EASD) in Lisbon...

Victoza: The Earlier The Better, New Study Shows

New data presented at the European Association for the Study of Diabetes (EASD) shows a significantly higher proportion of patients reached target HbA1c levels of <7% when Victoza (liraglutide [rDNA origin] injection) was administrated early in the treatment of type 2 diabetes to patients who had not received treatment before or had previously received only one oral anti-diabetic drug (OAD)...

Type 2 Drug Bydureon Proves More Effective Than Other Common Diabetes Treatments

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced new analyses from the DURATION-3 and DURATION-4 trials demonstrating patients treated with the investigational medication Bydureon (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments...

Photo Contest! Win a Nova Max Plus Glucose Meter and Test Strips

For all you diabetes slobs out there looking to clean up your diabetes act, here's your chance. ASweetLife has teamed up with Nova Diabetes Care, maker of the Nova Max Plus Glucose Monitoring System, for a contest/giveaway. We're offering you a chance to win one of two Nova Max Plus glucose meters/ketone testers.

JDRF Announces $100,000 Challenge for Development of Glucose Responsive Insulin

The Juvenile Diabetes Research Foundation (JDRF) and InnoCentive, Inc., the pioneer in open innovation and crowdsourcing, announced a $100,000 Challenge calling for innovative ways to approach the discovery and development of a glucose-responsive insulin drug as a means to treat insulin-dependent diabetes. The Challenge is open to the public and can be found on the InnoCentive website...

GlucaPen: The Way Glucagon Ought To Be

The current glucagon kits are not user-friendly, to say the least...